ArticlePublisher preview availableLiterature Review
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

The purpose of this response is to clarify points about the steps we took in a systematic review of the literature and to reaffirm our findings.
Response: “The Signal and the Noise”a response
to Clayton et al. (2021)
Lynn Rew
1
, Cara C. Young
1
, Maria Monge
2
& Roxanne Bogucka
3
1
School of Nursing, The University of Texas at Austin, Austin, TX, USA
2
Dell Medical School, The University of Texas at Austin, Austin, TX, USA
3
Life Science Library, The University of Texas at Austin, Austin, TX, USA
We appreciate the opportunity to respond to the com-
mentary provided on our review of the use of puberty
blockers to treat adolescents with gender dysphoria. Our
view is that each time a systematic literature review is
conducted and published, the scientic community is
presented with additional data and analyses from which
to form conclusions. As authors of such a review, we are
responsible for the integrity of our process, but acknowl-
edge that all readers may not agree with our interpreta-
tion of the ndings.
We initiated our review with a rigorous step-by-step
method of systematic review as outlined by Harris
Cooper (2017). Adherence to this method was the
strength of our study and it should be acknowledged
that we followed this method faithfully through comple-
tion with multiple investigators addressing each step in
the process. We also acknowledged the limitations of our
review, including the inclusion of only four databases.
We maintain that the databases utilized from the avail-
able institutional subscriptions were appropriate to
answer our research questions. The EMBASE data base
was not available at our university. We acknowledge that
our search terms did not identify the studies by Costa
et al. (2015), Joseph, Ting, and Butler (2019), and Klink,
Caris, Heijboer, van Trotsenburg, and Rotteveel (2015).
For this response, however, we sought and found these
publications. The Joseph et al. paper is a retrospective
chart review concerning bone density; these investiga-
tors concluded that there was a need for further study.
Klink et al. investigated bone mineral density (BMD) and
found that BMD was delayed and attenuated in adoles-
cents using GnRHa. Inclusion of these three papers
would have strengthened our review, but would not have
altered our conclusions.
The commentators wrote that The Costa et al. study
found no signicant difference in psychosocial function-
ing between a group of adolescents receiving puberty
blockers plus psychosocial support, and a group receiv-
ing only psychosocial support, at eighteen months (the
study end period)(Clayton, Malone, Clarke, Mason, &
DAngelo, 2021, p. 3). This selected quotation misses
other important statements written by Costa et al.
(2015). The purpose of the study by Costa et al. (2015)
was to assess the psychosocial functioning of adoles-
cents with gender dysphoria (GD), meeting diagnostic
criteria found in DSM-IV-TR across time. They hypothe-
sized that these adolescents would improve in psychoso-
cial functioning from baseline to after beginning
treatment with GnRHa. All adolescents in this study
were eligible for pubertal suppression as outlined in the
Standards of Care provided by WPATH; some were eligi-
ble immediately and others were delayed. All of these
adolescents (N=201) received psychological support
throughout the study period. Assessments were con-
ducted at baseline, and every 6 months for a total of four
evaluations over 18 months. Costa et al. reported,
Compared with baseline, GD adolescentspsychosocial
functioning was increasingly higher at each of the follow-
ing evaluations (gure 2). In particular, CGAS scores
were signicantly higher after 6 months of psychological
support (Time 0 vs. Time 1, p<.001). Also there was a
further signicant improvement 18 months from base-
line (Time 1 vs. Time 3, p=.02; table 2)(p. 2211). Costa
e al. also wrote, Finally, global functioning improved
steadily over time in GD adolescents receiving both psy-
chological support and GnRHa.Further, Consistently,
these results underline the importance of puberty sup-
pression for GD adolescentswell-being.Finally they
added, In conclusion, this study conrms the effective-
ness of puberty suppression for GD adolescents(p.
2212). This takeaway message is far different from the
one put forth by the commentators.
We further acknowledge that our search strategy
returned a total of 151 eligible, non-duplicated papers,
whereas 525 were identied by a review conducted by
the National Institute for Health and Care Excellence
(NICE, 2020). Because the NICE search strategies used
more search terms than those used in our review, they
yielded a larger set of search results. Ultimately, in an
evidence review, the number of studies that meet the
inclusion criteria is of greater importance than the num-
ber of studies recalled by the search strategies. Nine arti-
cles met the inclusion criteria for the NICE report, and
nine articles met the inclusion criteria for the Rew,
Young, Monge, and Bogucka (2021) report; four of these
were identical in both reports. The PubMed search strat-
egy we used found all nine of the included articles in the
NICE report, however, some of these did not meet our
inclusion criteria or failed to answer our research
questions.
In citing the work of Turban, King, Carswell, and Keu-
roghlian (2020) as well as all other studies in our review,
we did not make causal statements. We clearly wrote,
The most recent study by Turban et al. (2020) was the
rst to demonstrate that access to pubertal suppression
during adolescence was associated with decreased
©2021 Association for Child and Adolescent Mental Health.
Child and Adolescent Mental Health27, No. 3, 2022, pp. 263–264 doi:10.1111/camh.12534
... However, there is no robust empirical evidence that puberty blockers reduce suicidality or suicide rates (Biggs, 2020;Clayton et al., 2021). The authors of the paper, that was the basis for The Lancet's claim, subsequently clarified that they were not making any causal claims that puberty blockers decreased suicidality (Rew et al., 2021). Another paper, claiming to have found that barriers to gender-affirming care was associated with suicidality, had to withdraw this claim in a significant correction to their article (Zwickl et al., 2021). ...
... One review, Rew, Young, Monge, and Bogucka (2021a), appeared to claim a causal link between puberty blockers and decreased adult suicidality. However, following a published critique by Clayton et al. (2021) the authors clarified they were not making any causal claims and placed emphasis on their conclusion that more rigorous studies were required (Rew, Young, Monge, Bogucka, 2021b). ...
Article
Full-text available
This commentary compares two recently published informed consent recommendations for gender dysphoria. One key difference identified is in their assessment of the strength of the evidence base for the gender affirming treatment model. An evaluation of both authors' citations supports the claims of a weak evidence base for the use of puberty blockers and gender affirming hormonal treatments in youth with gender dysphoria. This commentary then reflects on the implications of this. In particular, it asks whether it would be best practice to provide gender affirming treatments for youth only under clinical research conditions, rather than as routine clinical practice.
Article
Full-text available
This commentary is a critique of a recent systematic review of the evidence for the use of puberty blockers for youth with gender dysphoria (GD) by Rew et al. (2021). In our view, the review suffers from several methodological oversights including the omission of relevant studies and suboptimal analysis of the quality of the included studies. This has resulted in an incomplete and incorrect assessment of the evidence base for the use of puberty blockers. We find that Rew et al.’s conclusions and clinician recommendations are problematic, especially when discussing suicidality. A key message of the review’s abstract appears to be that puberty blockers administered in childhood reduce adult suicidality. However, the study used for the basis of this conclusion (Turban et al., 2020) did not make a causal claim between puberty blockers and decreased adult suicidality. Rather, it reported a negative association between using puberty blockers and lifetime suicidal ideation. The study design did not allow for determination of causation. Our commentary concludes by demonstrating how the GD medical literature, as it moves from one publication to the next, can overstate the evidence underpinning clinical practice recommendations for youth with GD.
Article
Full-text available
Background Increasingly, early adolescents who are transgender or gender diverse (TGD) are seeking gender‐affirming healthcare services. Pediatric healthcare providers supported by professional guidelines are treating many of these children with gonadotropin‐releasing hormone agonists (GnRHa), which reversibly block pubertal development, giving the child and their family more time in which to explore the possibility of medical transition. Methods We conducted a critical review of the literature to answer a series of questions about criteria for using puberty‐blocking medications, the specific drugs used, the risks and adverse consequences and/or the positive outcomes associated with their use. We searched four databases: LGBT Life, PsycINFO, PubMed, and Web of Science. From an initial sample of 211 articles, we systematically reviewed 9 research studies that met inclusion/exclusion criteria. Results Studies reviewed had samples ranging from 1 to 192 (N = 543). The majority (71%) of participants in these studies required a diagnosis of gender dysphoria to qualify for puberty suppression and were administered medication during Tanner stages 2 through 4. Positive outcomes were decreased suicidality in adulthood, improved affect and psychological functioning, and improved social life. Adverse factors associated with use were changes in body composition, slow growth, decreased height velocity, decreased bone turnover, cost of drugs, and lack of insurance coverage. One study met all quality criteria and was judged ‘excellent’, five studies met the majority of quality criteria resulting in ‘good’ ratings, whereas three studies were judged fair and had serious risks of bias. Conclusion Given the potentially life‐saving benefits of these medications for TGD youth, it is critical that rigorous longitudinal and mixed methods research be conducted that includes stakeholders and members of the gender diverse community with representative samples.
Article
Background and objectives: Gonadotropin-releasing hormone analogues are commonly prescribed to suppress endogenous puberty for transgender adolescents. There are limited data regarding the mental health benefits of this treatment. Our objective for this study was to examine associations between access to pubertal suppression during adolescence and adult mental health outcomes. Methods: Using a cross-sectional survey of 20 619 transgender adults aged 18 to 36 years, we examined self-reported history of pubertal suppression during adolescence. Using multivariable logistic regression, we examined associations between access to pubertal suppression and adult mental health outcomes, including multiple measures of suicidality. Results: Of the sample, 16.9% reported that they ever wanted pubertal suppression as part of their gender-related care. Their mean age was 23.4 years, and 45.2% were assigned male sex at birth. Of them, 2.5% received pubertal suppression. After adjustment for demographic variables and level of family support for gender identity, those who received treatment with pubertal suppression, when compared with those who wanted pubertal suppression but did not receive it, had lower odds of lifetime suicidal ideation (adjusted odds ratio = 0.3; 95% confidence interval = 0.2-0.6). Conclusions: This is the first study in which associations between access to pubertal suppression and suicidality are examined. There is a significant inverse association between treatment with pubertal suppression during adolescence and lifetime suicidal ideation among transgender adults who ever wanted this treatment. These results align with past literature, suggesting that pubertal suppression for transgender adolescents who want this treatment is associated with favorable mental health outcomes.
Article
Background More young people with gender dysphoria (GD) are undergoing hormonal intervention starting with gonadotropin-releasing hormone analogue (GnRHa) treatment. The impact on bone density is not known, with guidelines mentioning that bone mineral density (BMD) should be monitored without suggesting when. This study aimed to examine a cohort of adolescents from a single centre to investigate whether there were any clinically significant changes in BMD and bone mineral apparent density (BMAD) whilst on GnRHa therapy. Methods A retrospective review of 70 subjects aged 12–14 years, referred to a national centre for the management of GD (2011–2016) who had yearly dual energy X-ray absorptiometry (DXA) scans. BMAD scores were calculated from available data. Two analyses were performed, a complete longitudinal analysis (n=31) where patients had scans over a 2-year treatment period, and a larger cohort over the first treatment year (n=70) to extend the observation of rapid changes in lumbar spine BMD when puberty is blocked. Results At baseline transboys had lower BMD measures than transgirls. Although there was a significant fall in hip and lumbar spine BMD and lumbar spine BMAD Z-scores, there was no significant change in the absolute values of hip or spine BMD or lumbar spine BMAD after 1 year on GnRHa and a lower fall in BMD/BMAD Z-scores in the longitudinal group in the second year. Conclusions We suggest that reference ranges may need to be re-defined for this select patient cohort. Long-term BMD recovery studies on sex hormone treatment are needed.
Article
Introduction: Puberty suppression by gonadotropin-releasing hormone analogs (GnRHa) is prescribed to relieve the distress associated with pubertal development in adolescents with gender dysphoria (GD) and thereby to provide space for further exploration. However, there are limited longitudinal studies on puberty suppression outcome in GD. Also, studies on the effects of psychological support on its own on GD adolescents' well-being have not been reported. Aim: This study aimed to assess GD adolescents' global functioning after psychological support and puberty suppression. Methods: Two hundred one GD adolescents were included in this study. In a longitudinal design we evaluated adolescents' global functioning every 6 months from the first visit. Main outcome measures: All adolescents completed the Utrecht Gender Dysphoria Scale (UGDS), a self-report measure of GD-related discomfort. We used the Children's Global Assessment Scale (CGAS) to assess the psychosocial functioning of adolescents. Results: At baseline, GD adolescents showed poor functioning with a CGAS mean score of 57.7 ± 12.3. GD adolescents' global functioning improved significantly after 6 months of psychological support (CGAS mean score: 60.7 ± 12.5; P < 0.001). Moreover, GD adolescents receiving also puberty suppression had significantly better psychosocial functioning after 12 months of GnRHa (67.4 ± 13.9) compared with when they had received only psychological support (60.9 ± 12.2, P = 0.001). Conclusion: Psychological support and puberty suppression were both associated with an improved global psychosocial functioning in GD adolescents. Both these interventions may be considered effective in the clinical management of psychosocial functioning difficulties in GD adolescents. Costa R, Dunsford M, Skagerberg E, Holt V, Carmichael P, Colizzi M. Psychological support, puberty suppression, and psychosocial functioning in adolescents with gender dysphoria. J Sex Med **;**:**-**.
Article
Context: Sex steroids are important for bone mass accrual. Adolescents with gender dysphoria (GD) treated with gonadotropin-releasing hormone analog (GnRHa) therapy are temporarily sex-steroid deprived until the addition of cross-sex hormones (CSH). The effect of this treatment on bone mineral density (BMD) in later life is not known. Objective: This study aimed to assess BMD development during GnRHa therapy and at age 22 years in young adults with GD who started sex reassignment (SR) during adolescence. Design and setting: This was a longitudinal observational study at a tertiary referral center. Patients: Young adults diagnosed with gender identity disorder of adolescence (DSM IV-TR) who started SR in puberty and had undergone gonadectomy between June 1998 and August 2012 were included. In 34 subjects BMD development until the age of 22 years was analyzed. Intervention: GnRHa monotherapy (median duration in natal boys with GD [transwomen] and natal girls with GD [transmen] 1.3 and 1.5 y, respectively) followed by CSH (median duration in transwomen and transmen, 5.8 and 5.4 y, respectively) with discontinuation of GnRHa after gonadectomy. Major outcome measures: How BMD develops during SR until the age of 22 years. Results and conclusion: Between the start of GnRHa and age 22 years the lumbar areal BMD z score (for natal sex) in transwomen decreased significantly from -0.8 to -1.4 and in transmen there was a trend for decrease from 0.2 to -0.3. This suggests that the BMD was below their pretreatment potential and either attainment of peak bone mass has been delayed or peak bone mass itself is attenuated.
E270-E275. National Institute for Health and Care Excellence (NICE). (2020). Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria
  • D Klink
  • M Caris
  • A Heijboer
  • M Van Trotsenburg
  • J Rotteveel
Klink, D., Caris, M., Heijboer, A., van Trotsenburg, M., & Rotteveel, J. (2015). Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. The Journal of Clinical Endocrinology & Metabolism, 100, E270-E275. National Institute for Health and Care Excellence (NICE). (2020). Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria. Available from: http://evidence.nhs.uk.